

# A recently published meta-analysis suggests 3M™ Veraflo™ Therapy could become your new standard of care.

A meta-analysis of 13 studies with 720 patients reported Veraflo Therapy had a significant effect on clinical outcomes when compared to standard of care including 3M™ V.A.C.® Therapy.



**Length of therapy reduced  
by more than half.**

(9.88 days vs 21.8 days,  $p=0.02$ )<sup>1,2</sup>



Wounds were **2.39 times  
more likely to close.**

( $p=0.01$ )<sup>1</sup>

**You know the science  
behind V.A.C.® Therapy.**

**Now, know the data  
behind Veraflo Therapy.**



To learn more about why you should **Start Smart** with Veraflo Therapy,  
please contact your local Sales Executive or visit [3M.ca/connect](http://3M.ca/connect).

**References:**

1. Gabriel A, Camardo M, O'Rourke E, Gold R, Kim PJ. Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis. *Plast Reconstr Surg*. 2021 Jan 1;147(1S-1):68S-76S. doi: 10.1097/PRS.0000000000007614. PMID: 33347065.
2. Camardo, Mark. "Veraflo Meta-Analysis Standardized and Non-Standardized Means.", 3M Internal Report, San Antonio, Texas, 2020.

Available in Canada from your authorized 3M-KCI distributors.  
KCI USA, Inc., a 3M Company  
KCI owned and operated by 3M Company

**KCI Medical Canada Inc.**  
75 Courtneypark Dr W, Unit 4  
Mississauga, ON  
L5W 0E3

**KCI USA, INC.**  
12930 IH 10 West  
San Antonio, TX  
78249

**NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.**

© 2021, 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. Used under license in Canada. 2103-19878-E PRA-PM-CA-00192 (03/21)